Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22952874 | 1.00 | DPP4 (0.46) | DPP4SLC7A5FAAHFAPDPP8 | |
| SCHEMBL7276787 | 1.00 | DPP4 (0.46) | DPP4SLC7A5FAAHFAPDPP8 | |
| SCHEMBL3367411 | 0.81 | — | — | |
| SCHEMBL19770803 | 0.81 | — | — | |
| SCHEMBL8941385 | 0.81 | — | — | |
| SCHEMBL28004804 | 0.79 | DPP4 (0.40) | DPP4FAAHDPP8DPP9DPP7 | |
| SCHEMBL476156 | 0.79 | DPP4 (0.40) | DPP4FAAHDPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL6162127 | 0.79 | FAAH (0.40) | DPP4FAAH | |
| SCHEMBL6610087 | 0.77 | SLC7A5 (0.34) | DPP4SLC7A5FAAHSLC1A3SLC1A2 | |
| SCHEMBL3151556 | 0.76 | FAAH (0.41) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428403-B2 | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-30 | — | — | US | disclosed |
| CN-115485273-B | N- (heterocyclyl and heterocyclylalkyl) -3-benzyl pyridin-2-amine derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2024-08-13 | — | — | CN | disclosed |
| US-20230192659-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192659-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192659-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-4126849-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115485273-A | N- (heterocyclyl and heterocyclylalkyl) -3-benzylpyridin-2-amine derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2022-12-16 | — | — | CN | disclosed |
| WO-2021202775-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021202775-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | WO | disclosed |
| EP-3773584-A1 | METHODS FOR PREPARING SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS | Arbutus Biopharma Corporation (CA) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019200109-A1 | METHODS FOR PREPARING SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-10-17 | — | — | WO | disclosed |
| EP-0291234-B1 | Peptidic human leukocyte elastase (HLE) inhibitors | ZENECA INC (US) | 1994-03-23 | — | — | EP | disclosed |
| US-5164371-A | HETEROCYCLIC KETONES | ICI AMERICAS INC. (US) | 1992-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428403-B2 | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | SSTR4, SSTR3, SSTR1 | DPP4 553/4885SLC7A5 2947/4885FAAH 1461/4885 |
| US-20230192659-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | SSTR4, SSTR3, SSTR1 | DPP4 553/4885SLC7A5 2947/4885FAAH 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.